Gene mutations linked to drug-resistant epilepsy in astrocytoma
Kanitpong Phabphal1, Anukoon Kaewborisutsakul2, Kittinun Leetanaporn3
1Unit of Neurology, Department of Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand.
Introduction:
Epilepsy is common in gliomas, particularly astrocytomas, even in patients who have undergone total tumor resection. Resistance to antiseizure drugs presents a significant challenge in managing epilepsy. Seizure outcomes after brain surgery for drug-resistant epilepsy (DRE) are heterogeneous and difficult to predict using models that evaluate current clinical, imaging, and electrophysiological variables. This study aimed to investigate possible correlations between genetic mutations and antiseizure resistance using whole-exome sequencing.
Methods:
Tumor samples from a medical biobank were subjected to whole-exome sequencing, and the contribution of 64 genes from a previous report was analyzed.
Results:
Fifteen patients had DRE. Compared to the patients who showed drug responsiveness, patients in the DRE group exhibited mutations in glutamate receptor genes (GRIA1, GRIK5, GRIN2B, or GRIN2C), ATRX, and the glutamate-S-transferase gene. No significant differences were found between the groups in terms of mutations in BRAF, Olig2, Ki-67, IDH, PIK3CA, p53, GRM, or BCL2A.
Discussion:
These findings suggest that somatic gene mutations are closely linked to DRE. Identifying the molecular basis of antiseizure drug resistance is crucial for improving the management of DRE.
Insights
Genetic mutations in glutamate receptor and other genes are linked to drug-resistant epilepsy (DRE) in glioma patients. Identifying these molecular markers is key to improving DRE management.
Area of Science:
- Neuroscience
- Genetics
- Oncology
Background:
- Epilepsy is a common complication of gliomas, including astrocytomas, persisting even after complete tumor removal.
- Drug-resistant epilepsy (DRE) poses a significant clinical challenge, with unpredictable seizure outcomes post-surgery.
- Current prediction models for DRE lack accuracy, utilizing clinical, imaging, and electrophysiological data.
Purpose of the Study:
- To investigate the correlation between specific genetic mutations and antiseizure drug resistance in glioma patients.
- To explore the potential of whole-exome sequencing in identifying molecular underpinnings of DRE.
Main Methods:
- Whole-exome sequencing was performed on tumor samples from a medical biobank.
- Analysis focused on the contribution of 64 pre-identified genes.
Main Results:
- Patients with DRE showed distinct mutations in glutamate receptor genes (GRIA1, GRIK5, GRIN2B, GRIN2C), ATRX, and a glutamate-S-transferase gene.
- No significant mutational differences were observed for BRAF, Olig2, Ki-67, IDH, PIK3CA, p53, GRM, or BCL2A between DRE and drug-responsive groups.
Conclusions:
- Somatic gene mutations are strongly associated with the development of DRE in glioma patients.
- Understanding the molecular basis of antiseizure drug resistance is critical for advancing DRE treatment strategies.
More Related Videos
07:39Co-culture of Glutamatergic Neurons and Pediatric High-Grade Glioma Cells Into Microfluidic Devices to Assess Electrical Interactions
Published on: November 17, 2021
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Related Concept Videos
02:56Treatment Resistant Cancers
01:14Antiepileptic Drugs: Glutamate Antagonists
01:24Arteries of the Lower Limbs
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...